2022 Press Releases
11-21-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
11-10-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022
10-05-22 ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022
09-14-22 ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
08-11-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
08-04-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
07-27-22 ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
07-07-22 ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
05-19-22 ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
05-12-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
05-10-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
05-05-22 Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
04-11-22 ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022